Efficacy and safety of SGLT2 inhibitors in preventing cardiovascular and renal events in patients with systemic lupus erythematosus and type 2 diabetes: comment on the article by Ma et al

Documenti analoghi

• Short‐term risk of cardiovascular events in people newly diagnosed with gout: comment on the article by Cipolletta et al
  di: Zichang Liu, et al.
  Pubblicazione: (2025)
• Endometriosis as a comorbidity in pregnant patients with systemic lupus erythematosus: comment on the article by Nguyen et al
  di: Maria I. Zervou, et al.
  Pubblicazione: (2026)
• Hydroxychloroquine dose after hospitalization for systemic lupus erythematosus: comment on the article by Nestor et al
  di: Berçemhan Sulu, et al.
  Pubblicazione: (2025)
• Drivers of subclinical vascular disease in systemic lupus erythematosus: comment on the article by Oliveira et al
  di: Biao Song, et al.
  Pubblicazione: (2025)
• Systemic lupus erythematosus and atherosclerosis progression risk: comment on the article by Papazoglou et al.
  di: Yusuf Ziya Sener, et al.
  Pubblicazione: (2025)